Other substances

Rigosertib

A kinase inhibitor, cell cycle inhibitor and apoptosis inducer.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Other treatment

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Rigosertib is a synthetic Ras mimetic. It inhibits proliferation in a spectrum of susceptible tumor cells (NCIt).

Rigosertib on DrugBank
Rigosertib on PubChem
Rigosertib on Wikipedia

 

Structure image - Rigosertib

COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels
GES1 cells; M0 and M1 macrophages 4.86

Decreases IL-6 secretion in M1 macrophages in vitro. Decreases ACE2 expression in GES-1 cells, however.

 Jun/27/2020
Export (.csv)